Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:APSCVE:BCTNASDAQ:IPANASDAQ:TH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPSAptose BiosciencesC$1.09-3.5%C$2.36C$1.02▼C$33.00C$46.93M1.365,094 shs3,079 shsBCTBriaCell TherapeuticsC$10.60-3.8%C$10.60C$3.50▼C$15.75C$168.68MN/A12,671 shs3,402 shsIPAImmunoPrecise Antibodies$1.11$0.62$0.27▼$1.16$50.80M0.122.51 million shs1.09 million shsTHTarget Hospitality$7.17-0.6%$7.02$4.00▼$11.10$716.42M1.85553,864 shs1.32 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPSAptose Biosciences-3.54%-22.14%-54.58%-77.34%-96.37%BCTBriaCell Therapeutics0.00%0.00%0.00%0.00%0.00%IPAImmunoPrecise Antibodies0.00%+10.45%+98.85%+183.16%+10.45%THTarget Hospitality-0.55%+1.27%-1.38%+7.98%-3.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAPSAptose BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies2.319 of 5 stars3.53.00.00.02.70.00.6THTarget Hospitality3.0628 of 5 stars3.43.00.00.02.71.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPSAptose Biosciences 4.00Strong BuyN/AN/ABCTBriaCell Therapeutics 0.00N/AC$15.0041.51% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00260.36% UpsideTHTarget Hospitality 2.75Moderate Buy$11.2556.90% UpsideCurrent Analyst Ratings BreakdownLatest APS, BCT, IPA, and TH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/31/2025THTarget HospitalityStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$5.00 ➝ $7.50(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPSAptose BiosciencesN/AN/AC$0.68 per share1.60C($0.92) per shareN/ABCTBriaCell TherapeuticsN/AN/AC$3.34 per share3.17C$3.60 per shareN/AIPAImmunoPrecise Antibodies$18.16M2.80N/AN/A$0.93 per share1.19THTarget Hospitality$386.27M1.84$1.48 per share4.86$4.26 per share1.68Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPSAptose Biosciences-C$154.69M-C$5.02N/A∞N/AN/A1,017.48%-136.29%N/ABCTBriaCell TherapeuticsN/A-C$0.38N/A∞N/AN/AN/AN/AN/AIPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-190.76%-88.87%-49.26%7/3/2025 (Estimated)THTarget Hospitality$71.26M$0.4316.6719.92N/A12.71%11.34%6.94%8/6/2025 (Estimated)Latest APS, BCT, IPA, and TH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025THTarget Hospitality-$0.02-$0.05-$0.03-$0.07$65.37 million$69.90 million3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPSAptose BiosciencesN/A0.39%N/AN/AN/ABCTBriaCell TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/ATHTarget HospitalityN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPSAptose Biosciences-117.371.055.41BCTBriaCell Therapeutics0.05129.63128.68IPAImmunoPrecise Antibodies0.452.322.11THTarget Hospitality0.101.971.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPSAptose Biosciences15.10%BCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.70%THTarget Hospitality32.40%Insider OwnershipCompanyInsider OwnershipAPSAptose Biosciences17.11%BCTBriaCell TherapeuticsN/AIPAImmunoPrecise Antibodies6.83%THTarget Hospitality68.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPSAptose Biosciences3143.06 millionN/ANot OptionableBCTBriaCell Therapeutics515.91 millionN/ANot OptionableIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableTHTarget Hospitality82099.36 million31.80 millionNot OptionableAPS, BCT, IPA, and TH HeadlinesRecent News About These CompaniesTarget Hospitality Corp. (NASDAQ:TH) Short Interest Up 23.9% in MayJune 19, 2025 | americanbankingnews.comShort Interest in Target Hospitality Corp. (NASDAQ:TH) Expands By 23.9%June 18, 2025 | marketbeat.com50,000 Shares in Target Hospitality Corp. (NASDAQ:TH) Acquired by Fortitude Advisory Group L.L.C.June 17, 2025 | marketbeat.comBank of America Corp DE Sells 99,159 Shares of Target Hospitality Corp. (NASDAQ:TH)June 14, 2025 | marketbeat.comTarget Hospitality (NASDAQ:TH) Upgraded at Wall Street ZenJune 14, 2025 | marketbeat.comTwo Sigma Investments LP Has $1.25 Million Holdings in Target Hospitality Corp. (NASDAQ:TH)June 5, 2025 | marketbeat.comBNP Paribas Financial Markets Sells 78,926 Shares of Target Hospitality Corp. (NASDAQ:TH)June 4, 2025 | marketbeat.comTH Q1 Earnings Call: Revenue Miss and Government Contract Shifts Shape 2025 OutlookMay 30, 2025 | msn.comAnalysts Offer Insights on Industrial Goods Companies: Target Hospitality (TH), Paccar (PCAR) and Carrier Global (CARR)May 22, 2025 | theglobeandmail.comTarget Hospitality Announces Seat on $4 Billion Multi-Year U.S. Government Strategic Sourcing VehicleMay 21, 2025 | prnewswire.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | insidermonkey.comTarget Hospitality Corp. (NASDAQ:TH) Q1 2025 Earnings Call TranscriptMay 20, 2025 | msn.comTarget Hospitality Corp. (TH) Q1 2025 Earnings Call TranscriptMay 19, 2025 | seekingalpha.comTarget Hospitality (NASDAQ:TH) Posts Better-Than-Expected Sales In Q1, Full-Year Outlook Slightly Exceeds ExpectationsMay 19, 2025 | msn.comTarget Hospitality (TH) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesMay 19, 2025 | zacks.comTarget Hospitality (TH) Reports Q1 Loss, Tops Revenue EstimatesMay 19, 2025 | zacks.comTarget Hospitality Reports First Quarter 2025 Results with Continued Focus on Pursuing Strong Strategic Growth PipelineMay 19, 2025 | prnewswire.comInsights into Target Hospitality's Upcoming EarningsMay 16, 2025 | benzinga.comHere's What to Know Ahead of Target Hospitality's Q1 EarningsMay 15, 2025 | zacks.comTarget Hospitality Announces First Quarter 2025 Earnings Release and Conference Call ScheduleMay 9, 2025 | prnewswire.comTarget Hospitality to Participate in Oppenheimer 20th Annual Industrial Growth ConferenceMay 6, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesCoca-Cola Stock Has Momentum, PepsiCo May Be the Better BuyBy Chris Markoch | May 29, 2025View Coca-Cola Stock Has Momentum, PepsiCo May Be the Better Buy3 Stocks Set to Double—And There's Still Time to BuyBy Nathan Reiff | June 12, 2025View 3 Stocks Set to Double—And There's Still Time to BuyNVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s WhyBy Thomas Hughes | May 29, 2025View NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why3 Overlooked Dividend Plays for Income in Volatile TimesBy Nathan Reiff | May 31, 2025View 3 Overlooked Dividend Plays for Income in Volatile TimesSalesforce’s Stock Price Presents an Opportunity to BuyBy Thomas Hughes | May 29, 2025View Salesforce’s Stock Price Presents an Opportunity to BuyAPS, BCT, IPA, and TH Company DescriptionsAptose Biosciences TSE:APSC$1.09 -0.04 (-3.54%) As of 06/27/2025 03:59 PM EasternAptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.BriaCell Therapeutics CVE:BCTC$10.60 -0.42 (-3.81%) As of 12/30/2021BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.ImmunoPrecise Antibodies NASDAQ:IPA$1.11 0.00 (0.00%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$1.10 -0.02 (-1.35%) As of 06/27/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Target Hospitality NASDAQ:TH$7.17 -0.04 (-0.55%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$7.06 -0.12 (-1.60%) As of 06/27/2025 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Target Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside QuantumScape Soars 30%: What Drove the Next-Gen EV Stock's Rally Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
